Context Therapeutics Stock (NASDAQ:CNTX)

Forecast Ownership Financials Chart

Previous Close

$0.59

52W Range

$0.55 - $3.62

50D Avg

$1.31

200D Avg

$1.75

Market Cap

$56.42M

Avg Vol (3M)

$2.29M

Beta

1.75

Div Yield

CNTX Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 20, 2021

Website

CNTX Performance

CNTX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-39.70M	$-29.92M	$-25.07M
Net Income	$-36.12M	$-26.73M	$-23.96M
EBITDA	$-39.70M	$-29.91M	$-25.06M
Basic EPS	$-0.38	$-0.46	$-1.50
Diluted EPS	$-0.38	$-0.46	$-1.50

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IMA	ImageneBio Inc
KLRS	Kalaris Therapeutics Inc
WHWK	Whitehawk Therapeutics Inc
CLNN	Clene Inc.
ORMP	Oramed Pharmaceuticals Inc.
IFRX	InflaRx N.V.
MGNX	MacroGenics, Inc.
CNTB	Connect Biopharma Holdings Limited
OVID	Ovid Therapeutics Inc.
STTK	Shattuck Labs, Inc.